EPAS1 and metabolic dysfunction-associated steatotic liver disease: Increased expression of HIF-1α and HIF-2α has been reported in many liver diseases, including nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), IR-induced liver injury, and hepatocellular carcinoma (HCC) [5–10].